The fusion protein FIP1L1-PDGFRa, a constitutively activated tyrosine kinase found in as many as half of those with the idiopathic hypereosinophilic syndrome, has emerged as a therapeutic target for imatinib [5], [37]. This evidence concerns the gene FIP1L1 and idiopathic hypereosinophilic syndrome.